文献速递肝病

工程化病毒猎手疫苗克服HBV免疫耐受

Engineered virus-hunter vaccine overcomes HBV immune tolerance.
PubMed 文献 · Gut · 2026-05-12

本研究构建SHARP疫苗平台,靶向HBsAg与DEC-205并偶联TLR7/8激动剂,在慢性HBV携带小鼠中增强DC抗原吞噬、成熟与提呈,SHARP-D265A(DA)因Fc沉默优化成为先导候选,逆转耐受微环境并建立持久病毒控制。

要点

  • SHARP平台双特异性抗体靶向HBsAg和DEC-205,偶联TLR7/8激动剂。
  • SHARP-D265A(DA)因Fc沉默优化、抗药抗体发生率更低而成为先导候选。
  • SHARP治疗使HBsAg低于检测限并出现抗-HBsAg,维持超过161天。

核心结论

  • SHARP疫苗策略主动捕获病毒,克服慢性HBV感染的耐受免疫微环境,为慢性HBV感染及其他免疫耐受疾病提供新策略。

研究设计与样本

  • 工程化SHARP疫苗平台,由靶向HBsAg和DEC-205的双特异性抗体偶联TLR7/8激动剂构成,在慢性HBV携带小鼠中评估疗效并探究免疫机制。

主要发现

  • 两种SHARP变体均增强DC的抗原吞噬、成熟和抗原提呈。
  • SHARP-D265A(DA)因Fc沉默优化成为先导候选,疗效更优且抗药抗体发生率更低。
  • SHARP治疗协同激活HBV特异性CD4+和CD8+ T细胞,逆转耐受微环境。
  • SHARP治疗实现持久病毒控制:HBsAg低于检测限,伴抗-HBsAg出现,维持超过161天并建立再攻击免疫记忆。

关键数值与推荐

  • 接受核苷(酸)类似物或干扰素治疗的患者中不足20%达到功能治愈。

临床怎么用

  • SHARP平台为慢性HBV感染提供新型治疗策略,先导候选SHARP-D265A(DA)在小鼠中显示持久病毒控制。

局限性

  • 疗效评估仅在慢性HBV携带小鼠中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Globally, an estimated 296 million individuals live with chronic hepatitis B virus (HBV) infection, carrying substantial risks of liver fibrosis, cirrhosis and hepatocellular carcinoma. Fewer than 20% of patients receiving nucleos(t)ide analogues or interferons achieve a functional cure, underscoring the urgent need for novel therapeutic strategies to improve clinical outcomes in patients with chronic HBV infection. OBJECTIVE: The aim of this study was to develop a 'virus-hunter vaccine' that hijacks HBV antigens as endogenous immunogens, reprogramming dendritic cells (DCs) to prime anti-HBV immunity, ultimately achieving a durable functional cure beyond current therapeutic limitations. DESIGN: We engineered the SHARP (Specific HBV Antigen-capturing and Rendering Promotor) vaccine platform, comprising a bispecific antibody targeting hepatitis B surface antigen (HBsAg) and DEC-205, conjugated with toll-like receptor 7/8 agonists. Therapeutic efficacy was assessed in chronic HBV carrier mice, with comprehensive investigation of immunological mechanisms. RESULTS: Both SHARP variants demonstrated enhanced antigen phagocytosis, maturation and antigen presentation of DCs. Notably, SHARP-D265A (DA) emerged as the lead candidate due to its optimised Fc silencing, showing superior therapeutic efficacy with a lower anti-drug antibody incidence. SHARP treatment reversed the tolerogenic microenvironment through coordinated activation of HBV-specific CD4+ and CD8+ T cells and established durable viral control: HBsAg was below the limit of detection, accompanied by the appearance of anti-HBsAg, which was maintained for more than 161 days with established immune memory against rechallenge. CONCLUSION: This innovative HBV vaccine strategy actively captures viruses, overcoming the tolerogenic immune microenvironment of chronic HBV infection, offering a novel strategy for the treatment of chronic HBV infection and other immune-tolerant diseases.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Chen X, Liu X, Xu T, et al. Engineered virus-hunter vaccine overcomes HBV immune tolerance. Gut. 2026. PMID: 41198172. doi:10.1136/gutjnl-2025-335806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。